References
- Yoneda T, Mundy G R. Monocytes regulate osteo-clast-activating-factor production by realising prosta-glandins. J Exp Med 1979; 150: 338–50
- Rodan S B, Rodan G A, Simmons H A, Walenga R W, Feinstein M B, Raisz L G. Bone resorptive factor produced by osteosarcoma cells with osteoblastic features is PGE2. Biochem Biophys Res Commun 1981; 102: 1358–65
- Stewart P J, Stern P H. Vertebral bone resorption in vitro: effects of parathyroid hormone, calcitonin, 1,25 dihydroxyvitamin D3, epidermal growth factor, prostg-landin E2 and estrogen. Calcif Tissue Int 1987; 40: 21–6
- Ueda K, Saito A, Nakano H, et al. Cortical hyperosto-sis following long-term administration of prostaglandin E, in infants with cyanotic congenital heart disease. J Pediatr 1980; 97: 834–6
- Raisz L G. Bone metabolism and its hormonal regulation. Triangel 1983; 22: 22–81
- Chyun Y S, Raisz L G. Stimulation of bone formation by prostaglandin E2. Prostaglandins 1984; 27: 97–103
- Kawase T, Orikasa M, Suzuki A. Phorbol ester (TPA) reduces prostaglandin E2 -stimulated CAMP production by desensitization of prostglandin E2 receptors in a clonal osteoblast-like cell line, MOB 3-4. Calcif Tissue Int 1991; 48: 167–75
- Sato K, Fuji Y, Kasono K, Saji M, Tsushima T, Shizume K. Stimulation of prostglandin E, and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. Biochem Biophys Res Commun 1986; 138: 618–24
- Dewhurst F E, Ago J M, Stashenko P. Interleukin 1 interacts synergistically with forskolin and isobutyl-methylxantine in stimulating bone resorption in organ culture. Calcif Tissue Int 1990; 47: 1–7
- Yu J H, Wells H, Moghadam B, Ryan W Y, Jr. Cyclic AMP formation and release by cultured bone cells stimulated with prostaglandin E2. Prostaglandins 1979; 17: 61–9
- Ribári O, Kiss J H, Tomity I, Jóri J, Stanzel Gy. The effect of Ipriflavone (Yambolap) on the otosclerotic process. Proceedings of the XIIth ORL World Congress, L Surján, Gy Bodó. Publishing House of the Hungarian Academy of Sciences, Budapest 1982; 547–9
- Ribári O, Sziklai I, Kiss J G. Proteolytic enzymes in otosclerosis. Significance of proteolytic enzymes in otosclerotic bone remodelling. ORL (Basel) 1987; 49: 282–6
- Sziklai I, Ribári O. The effect of flavone treatment on human otosclerotic ossicle organ cultures. Arch Otorhinolaryngol 1985; 242: 67–70
- Sziklai I, Ribári O. Die in-vitro Wirkung von Flav-onoid und Fluorid auf die relative Kollagensynthese der Explantate aus otosklerotischen Knochen. HNO-Prax 1990; 15: 29–34
- Ribári O, Sziklai I. The role of cyclic nucleotidases and PGE2 in the otosclerotic bone remodelling. Otosclerosis. Cellular and biochemical etiopathogenetic mechanisms, O Sala, A Martini. CIC Edizioni Internazionali, Roma 1987; 75–9
- Ribári O, Sziklai I. Effect of flavonoid on PGE2-induced alterations in percentage collagen synthesis in ossicle organ cultures. Acta Otolaryngol (Stockh) 1987; 103: 657–60
- Middleton E, Jr. The flavonoids. Trends Pharmacol Sci 1984; 00: 335–8
- Beretz A, Anton R, Stierle A, Cazenave J P. Role of cyclic AMP in the inhibition of human platelet aggregation by Quercetin, a flavonoid that potentiate the effect of prostacyclin. Biochem Pharm 1981; 31: 3597–600
- Peterkofsky B, Diegelman R. Use of a mixture of proteinase free collagenase for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry 1971; 10: 988–94
- Wong G L, Kocour B A. Differential sensitivity of os-teoclasts and osteoblasts suggests that PGE1 effects on bone may be mediated primarily through osteoclasts. Arch Biochem Biophys 1983; 224: 29–35
- Sziklai I, Komora V, Ribári O. Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis. Acta Chirurg Hung 1993; 33: 101–7